Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Rituxan Prescribers for NHL: Lymphoma Oncologists (US)

July 28, 2008
Lilly is replacing oine of its compounds with another in a subset of NSCLC
By a GLG Expert Contributor
Analysis of: Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer (jco.ascopubs.org)
Pemetrexed (lilly) with Cisplatinum is less toxic and may be more efficacious in a subset of patients with advanced NSCLC than Gemcitibine ( another Lilly compound) /Cisplatin combination. he real question is how this comapres to Avastin ( Genentech) or even the antibody Cetuximab ( Imclone) in...
July 28, 2008
OLD news, but positive results and higher visibility will definitely benefit Bayer
By a GLG Expert Contributor
Analysis of: Sorafenib in Advanced Hepatocellular Carcinoma (content.nejm.org)
The New England Journal of Medicine report confirms that Bayer/Onyx Nexavar prolongs median survival and time to progression in patients with advanced HCC. This trumor is a world wide health problem, so such positive news, although old, in a reputable journal, will lead to wider use of this oral...
July 28, 2008
Erbitux may add to chemotherapy in a subset of NSCLC patients
By a GLG Expert Contributor
Analysis of: Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy (jco.ascopubs.org)
In a US multicenter Phase II study, Erbitux ( Imclone) added to efficacy of Carboplatinum and Palcitaxel in a subset of NSCLC patients whose tumors had extra copies of EGFR that is targeted by Cetuxiamb. FISH techniques still has problems with standardization and larger number of patients are needed...
Michael Grossbard, MD, Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
July 7, 2008
One Drug Many Uses: Prove It
Analysis of: One drug, many uses. Good idea? (www.indystar.com)
Lilly has devoted substantial energy/expense in developing Cymbalta for many indications.  Is this at the expense of developing novel agents? 
Michael Grossbard, MD, Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
July 7, 2008
Can China Make Generics Better than They Make Toys
Analysis of: China Muscles In On The Generics Industry (www.pharmalot.com)
Several Chinese companies are set to enter the generic drug market ove the next year.  If these agents are demonstrated to be safe, they could have a large impact on the generic drug industry.
Michael Grossbard, MD, Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
July 7, 2008
Avastin Effecitve in Lung and Breast Cancer But is it Cost Effective?
Analysis of: Roche decision denies cancer drug to Britons (www.ft.com)
Roche has elected not to provide information on the cost effectiveness and clinical effectiveness of Avastin in breast cancer to the medicine advisory board of the British government.  As such, the drug will not be able for first line treatment of these diseases in Britain.
June 30, 2008
GSK's Lapatanib: ways from competing with Herceptin
By a GLG Expert Contributor
Analysis of: Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer (jco.ascopubs.org)
In a recent JCO article, Laptanib showed clinical efficacy and acceptable safety in a non-randomized trial involving newly diagnosed patients with advanced oe metastatic breast cancer. Larger trials are needed to confirm efficacy and explore if it is more potent than Genentech's Herceptin. For now,...
June 30, 2008
Avastin for front-line treatment of metastatic breast cancer: Not a big market
By a GLG Expert Contributor
Analysis of: Roche decision denies cancer drug to Britons (www.ft.com)
Avastin's recent FDA approval for m-breast cancer ( m-BCA) was lukewarm at best with no overall survival benefit yet and modest PFS data. European regulatory agencies usually require cost efficacy data and more strict data, which are not readily available for Roche/Genetech. The British market is not...
June 9, 2008
Transgene's vaccine for SCLC: Promising, BUT need to await survival and Phase III data
By a GLG Expert Contributor
Analysis of: Transgene's Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-Small Cell Lung Cancer Phase IIb Trial (www.pipelinereview.com)
Tarnsgene's cancer vaccine TG 4010 increased response rates and progression free survival when added to chemotherapy in patients with advanced small cell lung cancer. The overall survival rates and time to progression were not much different in the 2 treatment groups. The vaccine is novel and efficacy...
June 5, 2008
Trovax for renal cell carcinoma: not much potential
By a GLG Expert Contributor
Analysis of: Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer (www.pipelinereview.com)
The efficacy of the immunotherapeutic" vaccine" Trovax in 3 separate small phase II trials in combination with interferon alpha or IL-2 was modest at best. With availability of 3 targeted agents for this disease ( Nexavar, Sutent, and Torisel) , the chances of such as an agent are very limited.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 328

Analytics


Generated at 2009-01-09T07:00:23.050